These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36147706)

  • 21. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).
    Bell CF; Bobbili P; Desai R; Gibbons DC; Drysdale M; DerSarkissian M; Patel V; Birch HJ; Lloyd EJ; Zhang A; Duh MS;
    Clin Drug Investig; 2024 Mar; 44(3):183-198. PubMed ID: 38379107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of symptoms in COMET-ICE, a phase 2/3 study of sotrovimab for early treatment of non-hospitalized patients with COVID-19.
    Satram S; Ghafoori P; Reyes CM; Keeley TJH; Birch HJ; Brintziki D; Aldinger M; Alexander E; Lopuski A; Sarkis EH; Gupta A; Shapiro AE; Powers JH
    J Patient Rep Outcomes; 2023 Sep; 7(1):92. PubMed ID: 37702920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y; Ito T
    Viruses; 2023 May; 15(6):. PubMed ID: 37376600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.
    Razonable RR; Tulledge-Scheitel SM; Hanson SN; Arndt RF; Speicher LL; Seville TA; Larsen JJ; Ganesh R; O'Horo JC
    Open Forum Infect Dis; 2022 Oct; 9(10):ofac411. PubMed ID: 36213724
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies.
    Papadimitriou-Olivgeris M; Cipriano A; Guggisberg N; Kroemer M; Tschopp J; Manuel O; Golshayan D
    Transpl Int; 2022; 35():10721. PubMed ID: 36267693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants.
    Fujimoto K; Mutsuo S; Yasuda Y; Arasawa S; Tashima N; Iwashima D; Takahashi KI
    Infect Dis Rep; 2022 Dec; 14(6):996-1003. PubMed ID: 36547245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study.
    Abdalateef S; Al Meheiri NM; Nassef M; Shorrab AA; Hashimi OAR; Allam S; Alnaqbi MS; Al-Rifai RH
    BMJ Open; 2023 Jan; 13(1):e066095. PubMed ID: 36627160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
    Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
    Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-exposure prophylaxis with sotrovimab for Omicron (B.1.1.529) SARS-CoV-2 variant during the aplastic phase of autologous stem cell transplantation.
    Marcacci G; Coppola N; Madonna E; Becchimanzi C; De Pascalis S; D'Ovidio S; Crisci S; Maiolino P; De Filippi R; Pinto A
    Infect Agent Cancer; 2022 Aug; 17(1):41. PubMed ID: 35922822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab.
    Totschnig D; Doberer D; Haberl R; Wenisch C; Valipour A
    IDCases; 2022; 29():e01528. PubMed ID: 35694274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of lung transplant recipients infected with SARS-CoV-2/Omicron/B.1.1.529: a Nationwide German study.
    Kneidinger N; Hecker M; Bessa V; Hettich I; Wald A; Wege S; Nolde AB; Oldigs M; Syunyaeva Z; Wilkens H; Gottlieb J
    Infection; 2023 Jun; 51(3):749-757. PubMed ID: 36083405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy : A Cohort Study.
    McCreary EK; Lemon L; Megli C; Oakes A; Seymour CW;
    Ann Intern Med; 2022 Dec; 175(12):1707-1715. PubMed ID: 36375150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Sotrovimab in a cohort of pregnant women with a high risk of COVID 19 progression: a single-center experience.
    Frallonardo L; Vimercati A; Novara R; Lepera C; Ferrante I; Chiarello G; Cicinelli R; Mongelli M; Brindicci G; Segala FV; Santoro CR; Bavaro DF; Laforgia N; Cicinelli E; Saracino A; Di Gennaro F
    Pathog Glob Health; 2023 Jul; 117(5):513-519. PubMed ID: 36896940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of SARS-CoV-2 infection among lung transplant recipients: A single center retrospective study.
    Casutt A; Papadimitriou-Olivgeris M; Ioakeim F; Aubert JD; Manuel O; Koutsokera A
    Transpl Infect Dis; 2023 Feb; 25(1):e14007. PubMed ID: 36602439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients.
    Gliga S; Lübke N; Killer A; Gruell H; Walker A; Dilthey AT; Thielen A; Lohr C; Flaßhove C; Krieg S; Pereira JV; Seraphin TP; Zaufel A; Däumer M; Orth HM; Feldt T; Bode JG; Klein F; Timm J; Luedde T; Jensen BO
    Clin Infect Dis; 2023 Feb; 76(3):408-415. PubMed ID: 36189631
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sotrovimab Lowers the Risk of COVID-19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates.
    Saheb Sharif-Askari F; Ali Hussain Alsayed H; Tleyjeh I; Saheb Sharif-Askari N; Al Sayed Hussain A; Saddik B; Hamid Q; Halwani R
    Clin Pharmacol Ther; 2022 Dec; 112(6):1214-1223. PubMed ID: 35780295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Wogu AF; Wynia MK; Zane RD; Ginde AA
    medRxiv; 2022 Apr; ():. PubMed ID: 35411339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge.
    Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K
    J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.